Celostatin Lar contains Octreotide, a synthetic form of somatostatin, a natural hormone in the body that regulates the secretion of several other hormones. This long-acting release (LAR) version is specially formulated for monthly intramuscular injection. It is used to manage certain hormonal disorders and symptoms caused by hormone-secreting tumors.

Mechanism of Action:

Octreotide mimics the action of somatostatin by inhibiting the release of various hormones including growth hormone, insulin, glucagon, and serotonin. It also reduces blood flow to certain internal organs and slows down gastrointestinal motility.

In tumors, Octreotide helps reduce hormone overproduction, shrinking the tumor size in some cases or controlling related symptoms.

Uses:

Celostatin Lar is commonly used in:

• Acromegaly – a condition where the body produces too much growth hormone, leading to enlarged bones and tissues

• Neuroendocrine tumors – such as carcinoid tumors and VIPomas (tumors that produce vasoactive intestinal peptide)

• Control of severe diarrhea and flushing associated with these tumors

• Occasionally used in bleeding from esophageal varices in liver cirrhosis, though short-acting formulations are usually preferred for that

  Adverse Effects:

  Common side effects:

  • Abdominal pain, bloating, or nausea

  • Diarrhea or sometimes constipation

  • Headache or dizziness

  • Injection site pain or lumps

  • Gallstones with long-term use, due to reduced gallbladder movement